SEC Form 4 · accession 0001209191-17-013943
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William J Dawson
Officer — Chief Financial Officer
Period of report
Feb 21, 2017
Accepted (ET)
Feb 23, 2017 · 5:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 21, 2017 | A | 7,500 | $0.00 | A | 15,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $17.20 | Feb 21, 2017 | A | 45,000 | A | — | Feb 20, 2027 | Common Stock | 45,000 | 45,000 | D |
Explanation of responses
- F1The shares of Common Stock are to be acquired upon the vesting of certain Restricted Stock Units granted to the Reporting Person. The Restricted Stock Units shall vest as follows: 25% of the total number of Restricted Stock Units will vest on each of March 20, 2018, March 20, 2019, March 20, 2020 and March 20, 2021, subject to Reporting Person's Continuous Service as of each such date.
- F2The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with April 1, 2017, subject to Reporting Person's Continuous Service as of each such date.